Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Biomarkers of human papillomavirus (HPV) infection and risk of two increasing cancers

Award Number: U01CA195603
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2015
PERIOD OF PERFORMANCE END DATE: 08/31/2021

Group Awards By:

View Award Description

Biomarkers of human papillomavirus (HPV) infection and risk of two increasing cancers - DESCRIPTION (provided by applicant): Biomarkers of human papillomavirus (HPV) infection and risk of two increasing cancers Summary Oropharyngeal cancer and anal cancer have been recently highlighted in the annual `Report to the Nation on the Status of Cancer' as ebing the two cancers in the US that are increasing among both men and women. Our proposal focuses on these two cancers. Our pilot data from the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort indicate that circulating HPV16 E6 antibodies are present over 10 years before diagnosis in a large proportion of people who develop oropharyngeal cancer (35%), whilst being rare among controls (0.6%). We have subsequently identified HPV16 E6 antibodies in 29% of anal cancers and, again, being extremely rare among a separate group of controls (0.6%). These results are noteworthy as they indicate that a HPV-driven neoplastic process is present many years prior to diagnosis for both of these cancers, and raises the possibility that HPV16 E6 antibodies can be used as a highly specific biomarker to predict cancer onset. We have already established a cohort consortium in order to evaluate the sensitivity, specificity, and true latent period of HPV16 E6 antibody response before diagnosis, as well as survival outcome among all head and neck cancers for those who test positive. By bringing together 10 prospective cohorts from the US and Northern Europe, two populations where HPV infection now being recognized as the predominant cause of oropharynx cancer, we plan to identify 252 new oropharyngeal cancers and 180 anal cancer cases with pre-diagnostic blood samples available for analysis. We will also collect tumor tissue from 100 oropharynx cancer cases and 50 anal cases to evaluate the correlation between serology and tumor biomarkers of HPV infection.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2018	CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER	25 AVE TONY GARNIER	LYON				FRA	Cancer Detection and Diagnosis Research	000	4	1/31/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER	150 COURS ALBERT THOMAS	LYON		69008		FRA	Cancer Detection and Diagnosis Research	000	4	7/7/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $443,239 )
2018	2018	CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER	150 COURS ALBERT THOMAS	LYON		69008		FRA	Cancer Detection and Diagnosis Research	000	4	8/13/2018	NON-COMPETING CONTINUATION	$443,239
														Subtotal = $443,239

Issue Date FY: 2017 ( Subtotal = $466,874 )
2017	2017	CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER	150 COURS ALBERT THOMAS	LYON		69008		FRA	Cancer Detection and Diagnosis Research	000	3	8/14/2017	NON-COMPETING CONTINUATION	$466,874
														Subtotal = $466,874

Issue Date FY: 2016 ( Subtotal = $451,197 )
2016	2016	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER	150 COURS ALBERT TTHOMAS	LYON				FRA	Cancer Detection and Diagnosis Research	000	2	8/12/2016	NON-COMPETING CONTINUATION	$451,197
														Subtotal = $451,197

Issue Date FY: 2015 ( Subtotal = $483,879 )
2015	2015	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER	150 COURS ALBERT TTHOMAS	LYON				FRA	Cancer Detection and Diagnosis Research	001	1	9/2/2015	NEW	$31,513
2015	2015	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER	150 COURS ALBERT TTHOMAS	LYON				FRA	Cancer Detection and Diagnosis Research	000	1	9/1/2015	NEW	$452,366
														Subtotal = $483,879

Grand Total All Awards = $1,845,189

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Biomarkers of human papillomavirus (HPV) infection and risk of two increasing cancers

Award Number: U01CA195603

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2015

PERIOD OF PERFORMANCE END DATE: 08/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer